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The neurovascular unit (NVU) is a dynamic structure assembled by endothelial cells (EC),
a basement membrane (BM), perivascular astrocytes (PA), pericytes, and surrounding
neurons. The NVU regulates the passage of substances and cellular elements from the
intravascular space into the brain parenchyma. This function, also known as blood-brain
barrier (BBB), is regulated by the integrity of tight junctions proteins between EC, and the
interaction between PA and the basal lamina.The cytokine tumor necrosis factor-like weak
inducer of apoptosis (TWEAK) and its receptor fibroblast growth factor-inducible 14 (Fn14)
are abundantly expressed in the NVU. Here we will review data indicating that the interac-
tion betweenTWEAK and Fn14 in the endothelial cell-BM-astrocyte interface regulates the
function of the BBB following an ischemic/hypoxic injury, and that pharmacological inhibi-
tion of TWEAK-Fn14 is a promising target for the treatment of patients with neurological
diseases that have a direct impact on the structure and function of the NVU.
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THE TWEAK/Fn14 PATHWAY
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK)
is a member of the tumor necrosis factor (TNF) superfamily of
cytokines that is synthesized as a type II transmembrane protein
from which a soluble∼17 kDa ligand factor with biological activity
can be released [soluble TWEAK (sTWEAK)] (1). The membrane-
bound form of TWEAK has an extracellular TNF homology
domain (THD) that mediates the assembly of homotrimeric pro-
teins, and a stalk region that contains the recognition site for pro-
teolytic processing by serine proteases of the furin family. TWEAK
mRNA is expressed in a variety of tissues and cells, including brain,
heart, and lung (2), as well as human endothelial and smooth
muscle cells. Soluble TWEAK induces various cellular responses
in vitro, including cell proliferation (3–5), migration, differentia-
tion (6), angiogenesis (3), and the expression of pro-inflammatory
molecules such as IL-8, MCP-1, ICAM-1, and E-selectin in human
umbilical endothelial cells (EC) (7), and IL-6, IL-8, and ICAM-1
in astrocytes (8).
Tumor necrosis factor-like weak inducer of apoptosis activ-
ity is mediated via binding to fibroblast growth factor-inducible
14 (Fn14), a 14-KDa member of the TNF receptor superfamily
(9). Fn14 has a 28 amino acids residues-cytoplasmic tail with-
out a death domain. Instead, Fn14 contains a single binding
site for adapter proteins of the TNF receptor-associated factors
(TRAF) family (9–11). Fn14 is expressed in a variety of cells and
tissue types including tumor cell lines of non-lymphoid origin,
fibroblasts, and endothelial and epithelial cells. Furthermore, Fn14
expression is up-regulated following growth factor stimulation of
quiescent cell cultures, exposure to hypoxia (12, 13), oxidative
stress, chemical and mechanical injuries, inflammation, and tumor
growth (14). The TWEAK-Fn14 signal transduction pathway is
not fully understood, but it has been shown that TWEAK binding
to Fn14 activates the NF-κB (10), extracellular signal-regulated
kinase (ERK) (15), and c-Jun NH2-terminal kinase (JNK) (15)
signal transduction pathways.
In this review we will use the conceptual model of the neu-
rovascular unit (NVU) to discuss the role of TWEAK and Fn14
in the response of the brain to a hypoxic/ischemic injury, and will
discuss TWEAK/Fn14 as a potential target for the development
of therapeutic strategies to promote cell survival and improve the
neurological outcome in patients suffering from acute ischemic
stroke and other diseases of the central nervous system (CNS) that
affect the NVU.
THE NEUROVASCULAR UNIT
The NVU is a dynamic structure assembled by EC ensheated by a
basal lamina, and surrounded by astrocytic end-feet processes, per-
icytes, and neurons (Figure 1). One of the main functions of the
NVU is to regulate the passage of plasma components and cellular
elements from the intravascular space into the brain (16). This
barrier function, also known as the blood-brain barrier (BBB),
is determined not only by the integrity of the endothelium, but
most significantly by a functional interplay between EC, the basal
lamina, and perivascular astrocytes (PA).
The permeability of the endothelium is restricted by junctional
complexes assembled by adherens and tight junctions proteins (AJ
and TJ, respectively). AJ’s are formed mostly by vascular endothe-
lial (VE)-cadherin that mediates cell–cell adhesion via its interac-
tion with the actin cytoskeleton. TJ’s are located in the apical region
of the intercellular cleft and function as a “zipper” between the
apical and basolateral cell membranes. The transmembrane com-
ponents of the TJ include junctional adhesion molecule (JAM)-1,
occludin, and claudins. A set of accessory proteins, known as
zonula occludens (ZO)-1 and ZO-2, link these proteins with
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FIGURE 1 |The neurovascular unit (NVU) is assembled by endothelial
cells (EC) ensheated by a basement membrane (BM), embraced by
perivascular astrocytes (PVA) and pericytes (P), and surrounded by
neurons (N).
the cytoskeleton. Importantly, although disruption of AJ’s may
increase the permeability of the NVU, it is primarily the TJ’s
that confer the low paracellular permeability and high electrical
resistance that characterize the cerebrovascular endothelium.
The basement membrane (BM) forms an interface between EC
and PA, pericytes and neurons. It is composed of extracellular
matrix proteins such as laminin, collagen IV, fibronectin, and per-
lecan. About ∼95% of the basal lamina that encases the capillary
network is embraced by astrocytic end-feet processes (17), and
the opposite pole of each perivascular astrocyte contacts∼30,000
synapses (18).
The adhesion of EC and astrocytes to the basal lamina requires
the interaction of cell-adhesion receptors and their ligands in the
matrix. These receptors, known as integrins, play a key role in the
activation of cell signaling pathways in response to changes in the
extracellular environment, and in the regulation of the interac-
tion between EC and PA. In the NVU the integrin sub-unit β1 is
found in EC and astrocytes, whereas the integrin α6β4 is found in
astrocytic end-feet processes (19). These receptors interact with
laminin-1 and laminin-5 that are found in the basal lamina.
As it will be discussed below, the binding of TWEAK to Fn14 has
a direct effect on the composition of the basal lamina and on the
interaction between astrocytic end-feet processes and the BM. The
interplay between PA and the basal lamina is an important deter-
minant of the permeability of the NVU (20). Indeed, astrocytic-
derived factors have a direct effect on the attachment of PA to
the BM and on the integrity and distribution of interendothe-
lial TJs proteins, and detachment of astrocytic end-feet processes
from the basal lamina result in decreased transendothelial electri-
cal resistance (TEER) across the NVU with increased permeability
of the BBB.
Here we will review experimental data indicating that the
interaction between TWEAK and Fn14 regulate the interaction
between astrocytic end-feet processes and the basal lamina, and
that TWEAK/Fn14 play a central role in the regulation of the
permeability of the BBB and the survival of neurons associated
with each NVU. Furthermore, we will discuss the role of TWEAK
and Fn14 in the induction of a pro-inflammatory response in EC
and astrocytes, and the infiltration of inflammatory cells from the
intravascular space into the brain parenchyma.
BIOLOGICAL EFFECTS OF TWEAK-Fn14 ON THE
NEUROVASCULAR UNIT
TWEAK AND Fn14 EXPRESSION IN THE NEUROVASCULAR UNIT
Tumor necrosis factor-like weak inducer of apoptosis and Fn14
are abundantly expressed in the NVU. Indeed, TWEAK and Fn14
have been found in EC of the microcirculation (blood vessels
of <100µm of diameter), in PA, and in neurons of the cere-
bral cortex, caudate nucleus, putamen, substantia nigra, cerebellar
Purkinje cells, and spinal cord (12, 13). Interestingly, in vivo studies
suggest that the expression of TWEAK and Fn14 in the NVU is cell
type-specific. Accordingly, TWEAK appears to be expressed pri-
marily by EC while the highest level of Fn14 expression is detected
in PA and neurons. Furthermore, TWEAK has also been found
in pericytes (unpublished data), which not only have contractile
properties but also secrete several factors, such as angiopoietin-
1, that induce the expression of the TJ protein occludin in EC,
maintaining the high TEER characteristic of the BBB (21).
THE INTERACTION BETWEEN TWEAK AND Fn14 ACTIVATES THE NF-κB
PATHWAY IN THE NEUROVASCULAR UNIT
The NF-κB family includes homo- and heterodimers assembled by
the five members of the Rel transcription factor family (22). NF-
κB functional complexes are found in EC, PA, and neurons, where
they can be activated via two different pathways. In the classic
or canonic pathway, IκBα phosphorylation results in the release
of NF-κB, leading to its nuclear translocation and DNA bind-
ing. In the alternative pathway, IKK1-mediated phosphorylation
of the p100 precursor form of the p52 sub-unit leads to proteo-
somal processing of p100–p52, and nuclear translocation of p52-
containing NF-κB dimers (22, 23). Although it has been proposed
that TWEAK and Fn14 are able to activate both pathways, in vitro
and in vivo studies suggest that in the brain TWEAK/Fn14-induces
NF-κB pathway activation via the canonic pathway. Indeed, incu-
bation of brain microvascular EC, neurons and astrocytes with
TWEAK, or the intracerebral injection of TWEAK, leads to IκBα
phosphorylation with nuclear translocation of p65 but not p100
phosphorylation (24). However, it has been reported that in other
systems such as myoblasts and renal tubular cells, TWEAK may
also signal via the non-canonical NF-κB pathway (25, 26). In the
brain, treatment with TWEAK induces the expression of ICAM-1,
IL-6, and IL-8 in astrocytes (5), and TNF-α in astrocytes and neu-
rons (27). Importantly, the pro-inflammatory effect of TWEAK in
the NVU is not limited to astrocytes. Indeed, recent evidence indi-
cates that TWEAK induces an inflammatory response in human
cerebral microvascular EC that is associated with increase in the
permeability of the BBB (28). Together, these data indicate that
the interaction of TWEAK with Fn14 has an NF-κB-mediated
pro-inflammatory effect in the different components of the NVU
and, as it will be analyzed below, this has a direct effect on the
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permeability of the BBB, the development of cerebral edema, and
neuronal survival.
NEURONAL DEATH
Tumor necrosis factor-like weak inducer of apoptosis can induce
cell death in different tumor cell lines via TNF-α-dependent and -
independent mechanisms (29). However, this effect is weak and
in several experimental systems it requires co-incubation with
gamma interferon (1). In contrast, incubation with TWEAK seems
to have a stronger effect on neuronal death. Accordingly, treat-
ment of cerebral cortical neurons with TWEAK induces apoptotic
cell death (30) and the cleavage and accumulation of poly(ADP-
ribose) polymers. This effect is not mediated by TNF-α and instead
requires activation of the NF-κB pathway and a functional Fn14
receptor (31). These data suggest that, in contrast with tumor cell
lines, the interaction between TWEAK and Fn14 has a direct effect
on cell survival in cerebral cortical neurons.
TWEAK AND Fn14 IN THE ISCHEMIC BRAIN
ISCHEMIC STROKE
Ischemic stroke is the third cause of mortality a leading cause
of disability in the US. About ∼795,000 people suffer a stroke
every year, from which 600,000 are first attacks and 195,000 are
recurrences (32). Worldwide, it is estimated that 15 million people
suffer stroke each year. However, it is important to keep in mind
that in many countries ischemic stroke is underreported, and thus
this number may be significantly higher. A growing body of experi-
mental evidence in cell cultures (30), rodents (12, 13), and humans
(33) indicate that the interaction between TWEAK and Fn14 plays
a pivotal role in the response of the brain to an ischemic injury.
More importantly, the TWEAK/Fn14 pathway has emerged as a
target for the development of pharmacological strategies for the
treatment of acute ischemic stroke patients.
TWEAK AND Fn14 IN THE ISCHEMIC BRAIN
Studies with a murine model of cerebral ischemia indicate that the
expression of Fn14 mRNA increases in the ischemic tissue as early
as 30 min after the occlusion of the middle cerebral artery (here-
inafter referred to as MCAO). This effect peaks at 6–24 h, and
declines again 48–72 h later. In contrast, the effect on TWEAK
mRNA is less well characterized, and while some studies have
failed to detect a significant increase in TWEAK mRNA expression
in response to the ischemic injury (13), later observations have
shown a transient increase in TWEAK mRNA between 30 min
and 3 h of the onset of the ischemic injury. Additionally, it has
also been reported an effect of cerebral ischemia on TWEAK and
Fn14 protein expression. Interestingly, these changes have been
detected in the area surrounding the necrotic core, also known as
ischemic penumbra, and in those zones of the brain with develop-
ing cerebral edema (12, 13). The translational importance of these
reports is underscored by recent studies demonstrating that cere-
bral ischemia also induces the expression of TWEAK and Fn14 in
the brain of ischemic stroke patients (33).
INHIBITION OF TWEAK – Fn14 INTERACTION HAS A PROTECTIVE
EFFECT IN THE ISCHEMIC BRAIN
The effect of TWEAK/Fn14 inhibition on the outcome of the
ischemic injury has been studied with three different strategies:
the use of mice genetically deficient on either TWEAK (TWEAK
−/−) or Fn14 (Fn14−/−), or treatment with either a soluble Fn14-
Fc fusion protein, or anti-TWEAK monoclonal antibodies. The
first published studies reported that either the intraperitoneal
administration of anti-TWEAK monoclonal antibodies 10 min
before the induction of cerebral ischemia (30), or the intrac-
erebroventricular injection of an Fn14-Fc decoy receptor imme-
diately after (12, 13, 34) following the onset of ischemic stroke
results in a ∼30 and 40% decrease in the volume of the ischemic
lesion, respectively. These observations were supported by later
studies indicating that when compared to their littermate con-
trols, Fn14−/− mice exhibit ∼60% decrease in the volume of the
ischemic lesion following MCAO (34, 35). Additionally, it has been
reported that the neuroprotective effect of Fn14−/− deficiency in
the ischemic brain is mediated by the induction of the granulocyte-
colony stimulating factor (G-CSF) pathway (35). Interestingly,
the effect of genetic deficiency of TWEAK on the volume of the
ischemic lesion is less dramatic (∼20–40% decrease compared
to littermate controls). Together, these data indicate that phar-
macological inhibition of TWEAK/Fn14 with Fn14-Fc decoy or
TWEAK monoclonal antibodies may be an effective strategy for
the treatment of acute ischemic stroke. However, future studies
should define if the intravenous administration of these inhibitors
also has an effect on the volume of the ischemic lesion, and if
so, how far after the onset of the ischemic insult they can be
administered.
THE NEUROVASCULAR UNIT IN ISCHEMIC STROKE
Cerebral ischemia has a profound impact on the structure and
function of the NVU. Indeed, shortly after the onset of the ischemic
injury, those neurons located more distantly from a blood vessel
exhibit signs of irreversible injury and death. This is followed by a
rapid decrease in the expression of endothelial-β1 and astrocytic-
β1 and -α6β4 integrins, and degradation of laminin in the BM,
redistribution of interendothelial TJs proteins, and increase in the
permeability of the NVU, with the sub-sequent development of
cerebral edema and hemorrhagic transformation (36, 37). This
process is accompanied by the passage of inflammatory cells from
the intravascular space into the ischemic tissue where they fur-
ther increase the permeability of the BBB and have a deleterious
effect on the survival of those neurons located more proximally
to the blood vessel. As it will be discussed below, the interaction
between TWEAK and Fn14 in the NVU plays a pivotal role in
the development of cerebral edema, the infiltration of inflamma-
tory cells into the ischemic tissue, and neuronal death. These data
indicate that inhibition of TWEAK/Fn14 is an important target
for the development of therapeutic strategies aimed at maintain-
ing the structural and functional integrity of the NVU during
ischemic stroke.
TWEAK AND Fn14 EXPRESSION IN THE NEUROVASCULAR UNIT UNDER
ISCHEMIC CONDITIONS
Experimental data with an in vitro model of hypoxia show that
deprivation of oxygen and glucose increases the expression of
TWEAK and Fn14 in astrocytes, EC, and neurons. However,
hypoxia has an effect primarily on the expression of TWEAK in
EC and Fn14 in PA and neurons (24).
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THE INTERACTION BETWEEN TWEAK AND Fn14-INDUCES THE
PASSAGE OF INFLAMMATORY CELLS THROUGH THE ENDOTHELIAL
CELL-BASEMENT MEMBRANE-ASTROCYTE INTERFACE
NF-κB pathway activation plays a pivotal role in the development
of an inflammatory response in the ischemic brain. Earlier studies
have demonstrated that TWEAK induces NF-κB activation in EC,
astrocytes, and neurons, and that either treatment with an Fn14-Fc
decoy, or genetic deficiency of Fn14, abrogates cerebral ischemia-
induced Iκκβ and p65 phosphorylation in the ischemic brain (24).
Two events of special pathophysiological significance mediated by
the NF-κB pathway are the activation of matrix metalloproteinase-
9 (MMP-9) in PA, and the passage of inflammatory cells into the
ischemic brain parenchyma, both of which have direct effect on
the composition of the basal lamina and the permeability of the
BBB (see below).
MMP-9 is an NF-κB-regulated pro-inflammatory matrix met-
alloproteinase that has a direct effect on the composition of the
basal lamina (38). MMP-9 expression in the ischemic tissue not
only induces proteolytic degradation of the basal lamina but
also degradation of TJ proteins, which leads to the development
of cerebral edema, hemorrhagic transformation, and cell death.
The intracerebral injection of TWEAK induces MMP-9 activa-
tion, and either genetic deficiency of Fn14, or treatment with
Fn14-Fc decoy inhibits cerebral ischemia-induced MMP-9 acti-
vation. Importantly, the effect of Fn14-Fc decoy on MMP-9 is
dose-dependent (24).
The monocyte chemoattractant protein-1 (MCP-1) is an NF-
κB-regulated cytokine that has chemoattractant properties for
monocytes, memory T-lymphocytes, and natural killer cells.
Astrocytes are the main source of MCP-1 in the brain. The onset
of cerebral ischemia induces a progressive increase in MCP-1
expression in the ischemia tissue, associated with the passage of
leukocytes from the intravascular space into the ischemic brain
(39). Studies with an in vitro model of the BBB and an in vivo
model of cerebral ischemia indicate that the interaction between
astrocytic-derived TWEAK and Fn14-induces the expression of
MCP-1 in PA, leading to the recruitment of neutrophils from
the intravascular space into the ischemic tissue. This effect, medi-
ated by NF-κB pathway activation, is abrogated by treatment with
Fn14-Fc decoy (40). Together, the available data suggest not only
that TWEAK plays a central role regulating the process of ischemic
inflammation in the brain, but also indicate that TWEAK inhibi-
tion with Fn14-Fc decoy may have a role for the treatment of acute
ischemic stroke.
THE TWEAK-Fn14 PATHWAY MEDIATES THE DEVELOPMENT OF
ISCHEMIC EDEMA
The structural integrity of the NVU is compromised when the
cerebral blood flow falls below 10–15 ml/100 g/min, allowing the
passage of fluid, and proteins from the intravascular space into
the brain parenchyma (36, 37), with the development of cerebral
edema, which is a leading cause of death in the early phases of
ischemic stroke (41). Among the most important events under-
lying the development of ischemic cerebral edema are changes in
the composition of the basal lamina with detachment of astro-
cytic end-feet processes and redistribution of interendothelial TJs
proteins (42, 43). A role for TWEAK in the development of
cerebral edema was suggested by the observation that the injec-
tion of TWEAK directly into the cerebral cortex is followed by
detachment of PA from the BM, and the development of areas of
focal cerebral edema (24, 34). Sub-sequent studies demonstrated
that either genetic deficiency of Fn14 or treatment with Fn14-Fc
decoy inhibit MCAO-induced degradation of laminin in the basal
lamina (34). Importantly, the effect of TWEAK on the perme-
ability of the NVU in the ischemic brain is mediated by MMP-9
activation (24).
TWEAK AND NEURONAL DEATH: A DOUBLE EDGE SWORD
TWEAK and Fn14 induce neuronal death in the ischemic brain
A growing body of experimental evidence indicates that TWEAK
induces neuronal death. Early in vitro studies showed that 24 h
of incubation with TWEAK induces apoptotic cell death in neu-
rons and that this effect is mediated by NF-κB pathway activa-
tion (30). A role for TWEAK on neuronal death in the ischemic
brain was later demonstrated by the observation that treatment
with either anti-TWEAK neutralizing antibodies (30) or Fn14-Fc
decoy (13), or genetic deficiency of Fn14 (34), reduces the vol-
ume of the ischemic lesion following MCAO. Sub-sequent studies
reported that the interaction between TWEAK and Fn14-induces
poly(ADP-ribose) polymerase-1 (PARP-1) activation and that this
effect leads to caspase-3 cleavage and apoptotic neuronal death via
a TNF-α-independent mechanism (31).
TWEAK induces tolerance in the ischemic brain
Ischemic tolerance is an endogenous neuroprotective mechanism
whereby exposure to hypoxia/ischemia for a length of time or
intensity that is not severe enough to cause cell death (precondi-
tioning event) renders neurons resistant to a sub-sequent lethal
hypoxic/ischemic injury (44). The preconditioning event can pro-
tect the brain either very soon after its application (early precon-
ditioning) or after a delay of 24–72 h (delayed preconditioning).
Studies with an in vitro model of hypoxia and an in vivo model
of cerebral ischemia demonstrated that either treatment with sub-
lethal doses of TWEAK, or induction of endogenous of TWEAK
and Fn14 expression with sub-lethal hypoxia, renders neurons tol-
erant to a lethal hypoxic or ischemic injury applied 24 h later. This
protective effect is mediated by TWEAK’s ability to induce neu-
ronal TNF-α expression and ERK 1/2 activation, and is mediated
by phosphorylation of the B-cell lymphoma 2-associated death
promoter protein (Bad) (27).
CONCLUSION AND FUTURE DIRECTIONS
In the brain TWEAK and Fn14 play a pivotal role in the response
of the NVU an ischemic injury. Accordingly, the interaction
between TWEAK and Fn14 in the endothelial cell-BM-astrocyte
interface mediates the passage of inflammatory cells into the
ischemic tissue. Likewise, in vivo and in vitro data indicate that
TWEAK binding to Fn14 is followed by detachment of astro-
cytic end-feet processes from the BM, which leads to increase
in the permeability of the BBB and cerebral edema. In neurons,
TWEAK and Fn14 have a dual role. Hence, while the interac-
tion between TWEAK and Fn14 during the acute stages of the
ischemic injury induces neuronal death, exposure to TWEAK at
doses that do not produce cell death, renders neurons resistant
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against a sub-sequent hypoxic/ischemic injury (ischemic toler-
ance). Taken together, the data published to this data indicate
that TWEAK/Fn14 inhibitors may play a role in the treatment
of neurological conditions associated with increase in the perme-
ability of the BBB and hypoxia/ischemia-induced neuronal death.
The role of TWEAK as an inductor of ischemic tolerance is intrigu-
ing and future studies should define whether this cytokine has
a role protecting the brain of patients at high risk of ischemic
stroke.
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